News

Ovaprene is Daré’s investigational hormone-free monthly vaginal contraceptive, which is under clinical development to prevent pregnancy. Under the exclusive licence agreement, Bayer will commercialise Ovaprene after it is

Under the marketing authorisation application (MAA) submitted to the European Medicines Agency (EMA), the company has asked the regulator to review the potential use of fostemsavir in combination

The rolling submission allows completed sections of an NDA to be reviewed by the FDA on an ongoing basis. Specifically, Alnylam has submitted the non-clinical components to the

The new combined company, known as NeuroBo Pharmaceuticals began trading on the Nasdaq exchange under the ticker “NRBO” on December 31, 2019. NeuroBo will focus on advancing the

Based in Menlo Park of California, Dermira is involved in the development of novel therapies to treat patients with chronic skin conditions. As per terms of the deal,

These investigational agents have potential for use in HIV long-acting therapies for treatment and prevention, as well as cure strategies. HIV bNAbs are a class of immunotherapy agents

The Phase 3 study, which enrolled 2,838 adults, age 18-45 years, met both the primary and secondary endpoints. “We are thrilled with the results of the CONSTANT study,

Under the three-year collaboration, Empirico will use its Precision Insights Platform to determine therapeutic targets for indications and tissues, which are responsive to antisense technology. The Precision Insights

This exploratory Phase 2 trial, which is subject to the receipt of adequate funding, is designed to assess safety, pharmacokinetics and exploratory measures of function including cardiac, skeletal